3,4-双(三氟甲基)溴苯 | 320-29-6

• 物质功能分类: 有机原料 - 有机氟化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,4-双(三氟甲基)溴苯
• 中文别名: 3,4-双三氟甲基溴苯
• 英文名称: 3,5-ditrifluoromethylbromobenzene
• 英文别名: 4-bromo-1,2-bis-trifluoromethyl-benzene；4-Brom-1,2-bis-trifluormethyl-benzol；5-bromo-2-trifluoromethylbenzotrifluoride；4-bromo-1,2-bis(trifluoromethyl)benzene
• CAS: 320-29-6
• 化学式: C₈H₃BrF₆
• 分子量: 293.006
• InChiKey: SVWLLRHUNXRVOS-UHFFFAOYSA-N

物化性质

• 熔点：
  -48.0--47.0 °C
• 沸点：
  87.0 °C(Press: 40 Torr)
• 密度：
  1.697±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  3,4-双(三氟甲基)溴苯 在 tris-(dibenzylideneacetone)dipalladium(0) 、 [dicyclohexyl-[3,6-dimethoxy-2-(2,4,6-triisopropylphenyl)phenyl]phosphine][2-(2-aminophenyl)phenyl]methylsulfonyloxypalladium 、 caesium carbonate 、 sodium t-butanolate 、 2-二-叔丁膦基-2',4',6'-三异丙基联苯 作用下， 以 1,4-二氧六环 、 甲醇 、 甲苯 为溶剂， 反应 14.0h， 生成 C₃₂H₂₇F₉N₂O₃
  参考文献：
  名称：

  Synthesis and biological evaluation of a novel c-Myc inhibitor against colorectal cancer via blocking c-Myc/Max heterodimerization and disturbing its DNA binding

  摘要：

  DOI：

  10.1016/j.ejmech.2022.114779
• 作为产物：
  描述：

  邻苯二甲酸 在 sulfur tetrafluoride 、 氢氟酸 、 溴 作用下， 反应 12.0h， 以80%的产率得到3,4-双(三氟甲基)溴苯
  参考文献：
  名称：

  Kunshenko, B. V.; Omarov, V. O.; Muratov, N. N., Journal of Organic Chemistry USSR (English Translation), 1991, vol. 27, # 1.2, p. 108 - 112

  摘要：

  DOI：

文献信息

• [EN] PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY<br/>[FR] DÉRIVÉS DE PYRROLIDINE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, ET LEUR UTILISATION EN THÉRAPIE
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2014140310A1

  公开（公告）日：2014-09-18

  The present invention relates to pyrrolidine derivatives of formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.

  本发明涉及式(I)的吡咯烷衍生物，或其生理耐受盐。该发明涉及包含此类吡咯烷衍生物的药物组合物，以及利用此类吡咯烷衍生物进行治疗的用途。这些吡咯烷衍生物是GlyT1抑制剂。
• Efficient nickel(<scp>ii</scp>) naringenin-oxime complex catalyzed Mizoroki–Heck cross-coupling reaction in the presence of hydrazine hydrate
  作者：Jin-Yi Song、Yang Liu、Hong-Yan Zhao、Hua-Tao Han、Zhuo-Fei Li、Wei-Hao Guo、Wen-Yi Chu、Zhi-Zhong Sun

  DOI：10.1039/c7nj03148c

  日期：——

  A novel nickel(II) naringenin-oxime complex was designed, synthesized and characterized. Therein, nickel(II) naringenin oxime complex as an efficient catalyst was used in Mizoroki-Heck coupling reactions of aryl halides adhering electron-rich and electron-deficient substituents with styrene, methyl acrylate and divinylbenzene (DVB), respectively. The reaction proceeded efficiently under the alkaline

  设计，合成和表征了新型的柚皮苷镍-肟复合物。其中，镍（II）柚皮素肟配合物作为有效催化剂，分别用于粘附富电子和缺电子取代基的芳基卤化物分别与苯乙烯，丙烯酸甲酯和二乙烯基苯（DVB）的Mizoroki-Heck偶联反应中。在碱性条件下，在0.30 mol％Ni（II）柚皮素肟肟络合物，N2H4•H2O作为还原剂在80°C的EtOH中有效地进行了反应，提供了30种烯烃产物，中等至极好的收率，其中包含四种新产物。烯烃 新的催化体系不仅提供了一种廉价，高效，绿色的工艺方法，而且扩大了反应范围。
• Cyanation of haloaromatics utilizing catalysts generated in situ starting with NiCl2 or NiCl2 6H2O
  申请人：OCCIDENTAL CHEMICAL CORPORATION

  公开号：EP0384392A1

  公开（公告）日：1990-08-29

  Aromatic halide is converted to aromatic nitrile, e.g., p-chlorobenzotrifluoride is converted to 4-(trifluoromethyl)benzonitrile, utilizing Ni(Pφ₃)₃ as a catalyst where said catalyst is formed starting with NiCl₂ or NiCl₂·6H₂O where formation of said catalyst starting with NiCl₂ or NiCl₂·6H₂O and conversion of halide to nitrile are carried out in a single reactor vessel. The method comprises the steps of (a) forming catalyst by steps comprising (i) forming essentially dry Ni(Pφ₃)Cl₂ in situ in said reactor vessel starting with NiCl₂ or NiCl₂·6H₂O, (ii) reacting said essentially dry Ni(Pφ₃)₂Cl₂ with Pφ₃ in the presence of a reducing metal in C₂-C₅ alcohol or aprotic polar reaction solvent in said reactor vessel to produce Ni(Pφ₃)₃ catalyst therein, and (b) adding said halide into said reactor vessel to form a complex in C₂-C₅ alcohol or aprotic polar reaction solvent from said halide and said catalyst and adding alkali metal cyanide to convert halogen to CN and thereby produce nitrile. When anhydrous NiCl₂ is a starting material, steps (a)(i) and (a)(ii) are preferably carried out as a single step where anhydrous NiCl₂ and at least three equivalents of Pφ₃ are added to C₂-C₅ alcohol or aprotic polar solvent followed by addition of reducing metal powder and reaction is carried out to convert NiCl₂ to Ni(Pφ₃)₃ with intermediate formation of Ni(Pφ₃)₂Cl₂. When NiCl₂·6H₂O is a starting material, essentially dry Ni(Pφ₃)₂Cl₂ is formed in step (a)(i) by forming an admixture thereof with azeotrope-forming liquid (e.g., anhydrous C₂-C₅ alcohol or aprotic polar solvent or toluene) and heating to distill off water and forming essentially dry NiCl₂ which is converted to essentially dry Ni(Pφ₃)₂Cl₂ or the NiCl₂·6H₂O is reacted with Pφ₃ to form wet Ni(Pφ₃)₂Cl₂ which is dried by forming an azeotropic mixture and distilling to remove water or by heating or the NiCl₂·6H₂O is made essentially dry by heating with or without Pφ₃ present in the absence of reaction solvent to flash off water and form essentially dry NiCl₂ which is reacted with Pφ₃. The preferred C₂-C₅ alcohol is t-butanol which minimizes formation of hydrodehalogenation side-product in step (b) compared to other alcohols. The preferred aprotic polar solvent is acetonitrile.

  芳香卤化物可以转化为芳香腈，例如，使用Ni(Pφ₃)₃作为催化剂，p-氯苯三氟甲烷可以转化为4-(三氟甲基)苯腈。所述催化剂由NiCl₂或NiCl₂·6H₂O开始形成，其中利用单个反应器容器进行所述催化剂的形成，开始于NiCl₂或NiCl₂·6H₂O，同时进行卤代物到腈的转化。该方法包括以下步骤：(a)通过以下步骤形成催化剂：(i)在反应器容器中开始形成基本干燥的Ni(Pφ₃)Cl₂，开始于NiCl₂或NiCl₂·6H₂O，(ii)在还原金属和C₂-C₅醇或无极性极性反应溶剂的存在下，在反应器容器中反应所述基本干燥的Ni(Pφ₃)₂Cl₂和Pφ₃，以在其中产生Ni(Pφ₃)₃催化剂，以及(b)将所述卤代物加入所述反应器容器中，以从所述卤代物和所述催化剂中形成C₂-C₅醇或无极性极性反应溶剂的复合物，并添加碱金属氰化物以将卤素转化为CN并因此产生腈。当无水NiCl₂为起始材料时，步骤(a)(i)和(a)(ii)最好作为单个步骤进行，其中将无水NiCl₂和至少三当量的Pφ₃加入C₂-C₅醇或无极性极性溶剂中，然后加入还原金属粉末并进行反应，以转化NiCl₂为Ni(Pφ₃)₃，中间形成Ni(Pφ₃)₂Cl₂。当NiCl₂·6H₂O为起始材料时，在步骤(a)(i)中通过将其与共沸液形成的液体（例如，无水C₂-C₅醇或无极性极性溶剂或甲苯）混合并加热以蒸馏水并形成基本干燥的NiCl₂，然后将其转化为基本干燥的Ni(Pφ₃)₂Cl₂，或者通过将NiCl₂·6H₂O与Pφ₃反应形成湿的Ni(Pφ₃)₂Cl₂，然后通过形成共沸混合物并蒸馏去除水或加热干燥来将其干燥，或者通过在无反应溶剂的情况下加热或不加Pφ₃的情况下加热，使NiCl₂·6H₂O基本干燥并闪蒸水，形成基本干燥的NiCl₂，然后与Pφ₃反应。首选的C₂-C₅醇是叔丁醇，与其他醇相比可以最小化步骤(b)中的脱卤反应副产物的形成。首选的无极性极性溶剂是乙腈。
• Carbazole derivatives
  申请人：Hanson J. Gunnar

  公开号：US20070185184A1

  公开（公告）日：2007-08-09

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I: wherein n, R 1 , R 2 , R 3 , X, R 4 , R 5 , R 6 , R 8 , R 9 , and Y are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation and/or abnormal cell mitosis, such as cancer, inflammation and inflammation-associated disorders, and conditions associated with angiogenesis. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明涉及式I的化合物和药学上可接受的盐，其中n、R1、R2、R3、X、R4、R5、R6、R8、R9和Y的定义如本文所述。式I的化合物在治疗与细胞增殖和/或异常细胞有丝分裂相关的疾病和/或病症方面有用，例如癌症、炎症和炎症相关疾病以及与血管生成相关的病症。本发明还涉及包含本发明化合物的药物组合物以及使用这些化合物治疗上述疾病和病症的方法。
• Process for producing bis( trifluoromethyl)benzaldehyde
  申请人：——

  公开号：US20020042541A1

  公开（公告）日：2002-04-11

  The invention relates to a process for producing a bis(trifluoromethyl)benzaldehyde represented by the general formula [1]. This process includes reacting a mono-substituted bis(trifluoromethyl)benzene, represented by the general formula [2], with carbon monoxide and hydrogen in the presence of a catalyst and a base, the catalyst including a palladium compound and a phosphine, 1 wherein X is a halogen atom selected from F, Cl, Br and I, a trifluoromethanesulfonate group, or a pentafluoroethanesulfonate group.

  本发明涉及一种生产由通式[1]表示的双(三氟甲基)苯甲醛的方法。该方法包括在催化剂和碱的存在下，将由通式[2]表示的单取代的双(三氟甲基)苯与一氧化碳和氢反应，所述催化剂包括钯化合物和膦化合物，其中X是从F、Cl、Br和I中选择的卤素原子、三氟甲烷磺酸基或五氟乙烷磺酸基。